Cellectis
CLLS
27 hedge funds and large institutions have $16.9M invested in Cellectis in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 5 closing their positions.
13% more capital inflows, than outflows
Capital inflows: $5.41M | Capital outflows: $4.77M
0.84% more ownership
Funds ownership: 12.75% → 13.59% (+0.84%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 29 → 27 (-2)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$4.87M |
| 2 |
BGI
B Group Inc
Dallas,
Texas
|
+$259K |
| 3 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$148K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$39.2K |
| 5 |
Old Mission Capital
Chicago,
Illinois
|
+$37.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$3.33M |
| 2 |
Millennium Management
New York
|
-$638K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$274K |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$224K |
| 5 |
Morgan Stanley
New York
|
-$166K |
CLLS Hedge Fund Activity: Q1 2025 in Review
27 of the 7,481 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q1 2025, worth a combined $16.9M — down 27% from $23M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CLLS and 3 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was UBS AM, adding an estimated $4.87M. The largest seller was Capital International Investors, exiting entirely with an estimated $3.33M sold.
- 27 institutional investors held Cellectis (CLLS) as of Q1 2025, down from 29 in Q4 2024.
- Funds reported $16.9M of Cellectis stock for Q1 2025, down 27% quarter-over-quarter.
- 3 funds opened new Cellectis positions in Q1 2025 and 5 closed out, a net change of -2 holders.
- The largest Cellectis buyer in Q1 2025 was UBS AM, an estimated $4.87M added.
- The largest Cellectis seller in Q1 2025 was Capital International Investors, an estimated $3.33M sold.
Based on aggregated 13F filings for Q1 2025.